TORONTO--(BUSINESS WIRE)--Today, Juno Pharmaceuticals Canada (“Juno”), a leader in the commercialization of specialty pharmaceuticals, announced the acquisition of Omega Laboratories (“Omega”), one of Canada’s largest domestic specialty injectable pharmaceutical manufacturers. The new combined company is now one of the largest specialty generic injectable businesses in Canada with domestic manufacturing capabilities.
Health Canada Issues Recall of Omega Laboratories`s Sodium Chloride
The venture arms of three Big Pharmas have jumped in to seed a Swiss cancer startup with a bold twist on targeted therapy that, the founders say, could have effects on virtually every type of cancer.
Health Canada Issues Recall of Omega Laboratorie`s Thiamiject Injection
Catalent has invested $9 million in a clinical supply facility and Sagent has access to expanded manufacturing in Canada from its parent.
Omega Laboratories Ltd. Recalls Charac-25
Omega Laboratories Ltd. Recalled Sodium Chloride Bacteriostatic Inj. Due to Out of Specification Stability Result for pH
Omega Laboratories Ltd Recalls Sodium Chloride Injection Due to Failure of Specification Result For pH During Stability Testing
Mylan (MYL) Ups Bid for Perrigo (PRGO) to $32.7B, As M&A Hungry Hippos Continues
Mylan Raises Offer to Acquire Perrigo